TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy
To date, immune checkpoint inhibitors have been successively approved and widely used in clinical cancer treatments, however, the overall response rates are very low and almost all cancer patients eventually progressed to drug resistance, this is mainly due to the intricate tumor microenvironment an...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.716710/full |
id |
doaj-415a1fc261a74eaf997267459b19a6d2 |
---|---|
record_format |
Article |
spelling |
doaj-415a1fc261a74eaf997267459b19a6d22021-09-04T08:54:05ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-09-011210.3389/fimmu.2021.716710716710TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer ImmunotherapyHui Qiu0Hui Qiu1Zhiying Shao2Xin Wen3Xin Wen4Jinghua Jiang5Qinggong Ma6Yan Wang7Long Huang8Xin Ding9Xin Ding10Longzhen Zhang11Longzhen Zhang12Cancer Institute, Xuzhou Medical University, Xuzhou, ChinaDepartment of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, ChinaCancer Institute, Xuzhou Medical University, Xuzhou, ChinaCancer Institute, Xuzhou Medical University, Xuzhou, ChinaDepartment of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, ChinaDepartment of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, ChinaDepartment of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, ChinaDepartment of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, ChinaDepartment of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, ChinaCancer Institute, Xuzhou Medical University, Xuzhou, ChinaDepartment of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, ChinaCancer Institute, Xuzhou Medical University, Xuzhou, ChinaDepartment of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, ChinaTo date, immune checkpoint inhibitors have been successively approved and widely used in clinical cancer treatments, however, the overall response rates are very low and almost all cancer patients eventually progressed to drug resistance, this is mainly due to the intricate tumor microenvironment and immune escape mechanisms of cancer cells. One of the main key mechanisms leading to the evasion of immune attack is the presence of the immunosuppressive microenvironment within tumors. Recently, several studies illustrated that triggering receptor expressed on myeloid cells-2 (TREM2), a transmembrane receptor of the immunoglobulin superfamily, was a crucial pathology-induced immune signaling hub, and it played a vital negative role in antitumor immunity, such as inhibiting the proliferation of T cells. Here, we reviewed the recent advances in the study of TREM2, especially focused on its regulation of tumor-related immune signaling pathways and its role as a novel target in cancer immunotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2021.716710/fullTREM2immune checkpoint inhibitorimmunosuppressive myeloid cellcancer immunotherapyimmune microenvironment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hui Qiu Hui Qiu Zhiying Shao Xin Wen Xin Wen Jinghua Jiang Qinggong Ma Yan Wang Long Huang Xin Ding Xin Ding Longzhen Zhang Longzhen Zhang |
spellingShingle |
Hui Qiu Hui Qiu Zhiying Shao Xin Wen Xin Wen Jinghua Jiang Qinggong Ma Yan Wang Long Huang Xin Ding Xin Ding Longzhen Zhang Longzhen Zhang TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy Frontiers in Immunology TREM2 immune checkpoint inhibitor immunosuppressive myeloid cell cancer immunotherapy immune microenvironment |
author_facet |
Hui Qiu Hui Qiu Zhiying Shao Xin Wen Xin Wen Jinghua Jiang Qinggong Ma Yan Wang Long Huang Xin Ding Xin Ding Longzhen Zhang Longzhen Zhang |
author_sort |
Hui Qiu |
title |
TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy |
title_short |
TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy |
title_full |
TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy |
title_fullStr |
TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy |
title_full_unstemmed |
TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy |
title_sort |
trem2: keeping pace with immune checkpoint inhibitors in cancer immunotherapy |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2021-09-01 |
description |
To date, immune checkpoint inhibitors have been successively approved and widely used in clinical cancer treatments, however, the overall response rates are very low and almost all cancer patients eventually progressed to drug resistance, this is mainly due to the intricate tumor microenvironment and immune escape mechanisms of cancer cells. One of the main key mechanisms leading to the evasion of immune attack is the presence of the immunosuppressive microenvironment within tumors. Recently, several studies illustrated that triggering receptor expressed on myeloid cells-2 (TREM2), a transmembrane receptor of the immunoglobulin superfamily, was a crucial pathology-induced immune signaling hub, and it played a vital negative role in antitumor immunity, such as inhibiting the proliferation of T cells. Here, we reviewed the recent advances in the study of TREM2, especially focused on its regulation of tumor-related immune signaling pathways and its role as a novel target in cancer immunotherapy. |
topic |
TREM2 immune checkpoint inhibitor immunosuppressive myeloid cell cancer immunotherapy immune microenvironment |
url |
https://www.frontiersin.org/articles/10.3389/fimmu.2021.716710/full |
work_keys_str_mv |
AT huiqiu trem2keepingpacewithimmunecheckpointinhibitorsincancerimmunotherapy AT huiqiu trem2keepingpacewithimmunecheckpointinhibitorsincancerimmunotherapy AT zhiyingshao trem2keepingpacewithimmunecheckpointinhibitorsincancerimmunotherapy AT xinwen trem2keepingpacewithimmunecheckpointinhibitorsincancerimmunotherapy AT xinwen trem2keepingpacewithimmunecheckpointinhibitorsincancerimmunotherapy AT jinghuajiang trem2keepingpacewithimmunecheckpointinhibitorsincancerimmunotherapy AT qinggongma trem2keepingpacewithimmunecheckpointinhibitorsincancerimmunotherapy AT yanwang trem2keepingpacewithimmunecheckpointinhibitorsincancerimmunotherapy AT longhuang trem2keepingpacewithimmunecheckpointinhibitorsincancerimmunotherapy AT xinding trem2keepingpacewithimmunecheckpointinhibitorsincancerimmunotherapy AT xinding trem2keepingpacewithimmunecheckpointinhibitorsincancerimmunotherapy AT longzhenzhang trem2keepingpacewithimmunecheckpointinhibitorsincancerimmunotherapy AT longzhenzhang trem2keepingpacewithimmunecheckpointinhibitorsincancerimmunotherapy |
_version_ |
1717815199721848832 |